<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650831</url>
  </required_header>
  <id_info>
    <org_study_id>HP-MBI-0212</org_study_id>
    <nct_id>NCT01650831</nct_id>
  </id_info>
  <brief_title>Show Equivalence of the Modified BreathID Compared to Currently Approved BreathID in H.Pylori Detection</brief_title>
  <official_title>Clinical Study to Evaluate the Equivalence of the Modified BreathID Compared to Currently Approved BreathID System in Detection of H.Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exalenz Bioscience LTD.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm equivalence of a new generation breath analyzer
      (Modified BreathID) in its ability to detect H. pylori compared to the currently approved
      BreathID® System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ¹³C-Urea Breath Test (UBT) is a non-invasive test for detecting the presence of
      Helicobacter pylori (H. pylori) infection by the organism's urease activity. In the presence
      of H. pylori, the ingestion of urea, labeled with the non-radioactive isotope 13C, results in
      production of labeled 13CO2, which can be quantified in expired breath. Each test is
      performed using a test kit consisting of a 13C-urea tablet and citrica powder to be dissolved
      in tap water (&quot;13C-urea solution&quot;). Before and after ingestion of the 13C-urea solution,
      samples of exhaled breath can be collected using a nasal cannula for real-time analysis and
      comparison to baseline concentrations. The patient's exhaled breath is analyzed and the ratio
      between 13CO2 and 12CO2 is computed. The patient is considered H. pylori positive when the
      difference between the ratios exceeds a predefined threshold (5 delta over baseline (DOB)).
      The current device marketed by Exalenz is large and costly. Exalenz has built a smaller,
      cheaper and more reliable new generation device for this application. Equivalence is being
      demonstrated in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Dichotomous (Presence/Absence of H.Pylori) Outcome Agreement in Diagnosis of H. Pylori</measure>
    <time_frame>25 minutes</time_frame>
    <description>The marketed (cleared) BreathID device and the investigational modified new generation BreathID device will measure simultaneously before (baseline) and after ingestion of substrate. The subject will be connected to both devices. The maximum time of measurement is 25 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive/Negative for H.Pylori With Cleared BreathID</measure>
    <time_frame>1 hour</time_frame>
    <description>The amount of subjects that produced positive/negative results with cleared BreathID device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive/Negative for H.Pylori With Modified BreathID</measure>
    <time_frame>1 hour</time_frame>
    <description>The amount of subjects that produced positive/negative results for H.pylori with modified BreathID</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Suspicion of Being Infected With H.Pylori</condition>
  <arm_group>
    <arm_group_label>Clinical Suspicion of Hpylori</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects arriving at clinic with suspicion of having Helicobacter infection due to symptoms such as reflux, ulcer, gastric cancer and other clinical gastric conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Modified BreathID</intervention_name>
    <description>A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula</description>
    <arm_group_label>Clinical Suspicion of Hpylori</arm_group_label>
    <other_name>BreathID Hp</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be at least 18 years of age

          2. Present with clinical indication of H. pylori

          3. Have the ability and willingness to sign the Informed Consent Form-

        Exclusion Criteria:

          1. Current serious disease

          2. Participation in other trials

          3. Antibiotics and/or Bismuth preparations for four (4) weeks prior to test

          4. PPI or H2 blockers for two (2) weeks prior to test

          5. Childbearing or breastfeeding women

          6. Based on opinion of investigator, subject should not be enrolled in this trial

          7. Allergy to citrus juice

          8. Post -eradication therapy for H. pylori
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unimed Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unimed Center</name>
      <address>
        <city>East Brunswick</city>
        <state>New Jersey</state>
        <zip>08816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007 Aug;102(8):1808-25. Epub 2007 Jun 29.</citation>
    <PMID>17608775</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <results_first_submitted>May 28, 2013</results_first_submitted>
  <results_first_submitted_qc>July 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 2, 2013</results_first_posted>
  <last_update_submitted>March 17, 2016</last_update_submitted>
  <last_update_submitted_qc>March 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter Pylori</keyword>
  <keyword>13C Urea Breath Test</keyword>
  <keyword>BreathID</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult subjects with suspected infection of Helicobacter Pylori due to symptoms were offered to do the test on a walk- in basis were recruited. 113 Subjects were recruited in October and November 2012 in a private medical clinic.</recruitment_details>
      <pre_assignment_details>Subjects with prior knowledge of Helicobacter Pylori infection or taking proton pump inhibitors within the two week period before the test, were not included.Only one test per subject was done.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Clinical Suspicion of Hpylori</title>
          <description>All subjects arriving at clinic with suspicion of having Helicobacter infection due to symptoms such as reflux, ulcer, gastric cancer and other clinical gastric conditions
Modified BreathID : A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clinical Suspicion of Hpylori</title>
          <description>All subjects arriving at clinic with suspicion of having Helicobacter infection due to symptoms such as reflux, ulcer, gastric cancer and other clinical gastric conditions
Modified BreathID : A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="113"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="16.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Dichotomous (Presence/Absence of H.Pylori) Outcome Agreement in Diagnosis of H. Pylori</title>
        <description>The marketed (cleared) BreathID device and the investigational modified new generation BreathID device will measure simultaneously before (baseline) and after ingestion of substrate. The subject will be connected to both devices. The maximum time of measurement is 25 minutes.</description>
        <time_frame>25 minutes</time_frame>
        <population>Only subjects that had no recent knowledge of existing H.pylori infection and who met all protocol criteria and had no major protocol deviations, were included in the final analysis set (PP-per protocol).</population>
        <group_list>
          <group group_id="O1">
            <title>Clinical Suspicion of Hpylori</title>
            <description>All subjects arriving at clinic with suspicion of having Helicobacter infection due to symptoms such as reflux, ulcer, gastric cancer and other clinical gastric conditions
Modified BreathID : A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Dichotomous (Presence/Absence of H.Pylori) Outcome Agreement in Diagnosis of H. Pylori</title>
          <description>The marketed (cleared) BreathID device and the investigational modified new generation BreathID device will measure simultaneously before (baseline) and after ingestion of substrate. The subject will be connected to both devices. The maximum time of measurement is 25 minutes.</description>
          <population>Only subjects that had no recent knowledge of existing H.pylori infection and who met all protocol criteria and had no major protocol deviations, were included in the final analysis set (PP-per protocol).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive agreeement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="81.57" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative agreement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8" lower_limit="88.98" upper_limit="99.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Positive/Negative for H.Pylori With Cleared BreathID</title>
        <description>The amount of subjects that produced positive/negative results with cleared BreathID device</description>
        <time_frame>1 hour</time_frame>
        <population>Per protocol positive/negative when testing with marketed BreathID</population>
        <group_list>
          <group group_id="O1">
            <title>Marketed BreathID Positive</title>
            <description>Cleared BreathID subjects that were found to be positive for H.pylori</description>
          </group>
          <group group_id="O2">
            <title>Marketed BreathID Negative</title>
            <description>Cleared BreathID subjects that were found to be negative for H.pylori</description>
          </group>
        </group_list>
        <measure>
          <title>Positive/Negative for H.Pylori With Cleared BreathID</title>
          <description>The amount of subjects that produced positive/negative results with cleared BreathID device</description>
          <population>Per protocol positive/negative when testing with marketed BreathID</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Positive/Negative for H.Pylori With Modified BreathID</title>
        <description>The amount of subjects that produced positive/negative results for H.pylori with modified BreathID</description>
        <time_frame>1 hour</time_frame>
        <population>Per protocol subjects tested with modified BreathID</population>
        <group_list>
          <group group_id="O1">
            <title>Positive Modified BreathID</title>
            <description>The amount of subjects that produced positive results for H.pylori with modified BreathID.</description>
          </group>
          <group group_id="O2">
            <title>Negative Modified BreathID</title>
            <description>The amount of subjects that produced negative results for H.pylori with modified BreathID.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive/Negative for H.Pylori With Modified BreathID</title>
          <description>The amount of subjects that produced positive/negative results for H.pylori with modified BreathID</description>
          <population>Per protocol subjects tested with modified BreathID</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Clinical Suspicion of Hpylori</title>
          <description>All subjects arriving at clinic with suspicion of having Helicobacter infection due to symptoms such as reflux, ulcer, gastric cancer and other clinical gastric conditions
Modified BreathID : A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Avraham Hershkowitz, Clinical Trials Manager</name_or_title>
      <organization>Exalenz.Bioscience Ltd.</organization>
      <phone>+972-8-9737513</phone>
      <email>avrahamh@exalenz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

